Welcome!

News Feed Item

Vaccine Industry Watchdog Responds to Forbes' Defense of Mercury-Laced Vaccinations

Dr. Brian Hooker, PhD, says Forbes misrepresented congressional record and CDC studies

CHARLOTTE, N.C., Feb. 28, 2014 /PRNewswire-iReach/ -- Last week, PhD biochemist Brian Hooker created a stir when he announced he had obtained sensitive documents from the CDC (Centers for Disease Control and Prevention) through Freedom of Information Act (FOIA) requests. According to Hooker, these documents implicated the vaccine preservative Thimerosal (50% mercury by weight) in causing autism and other neurodevelopmental disorders, revealing what he says CDC officials had long known, but never disclosed publicly: a 7.6-fold increase in autism during infancy after exposure. Emily Willingham, who frequently editorializes in support of the vaccine program, responded in Forbes by criticizing a news story that went viral on the subject of Dr. Hooker's FOIA revelations.

(Photo: http://photos.prnewswire.com/prnh/20140228/MN73622)

Dr. Hooker methodically itemized "misrepresentations and outright errors" that he says appeared in Forbes.com. "Willingham either confused two CDC studies or intentionally deceived Forbes' readers," said Hooker. "There was one concealed study that found a very high association between Thimerosal and autism. That was the study that was kept from the public which I obtained. And there was a later study by the same researcher – CDC-paid epidemiologist Thomas Verstraeten – who had watered down the results of the earlier study to appear as if there were no association between Thimerosal and autism. That second study was made public even though it was fraudulent.  Willingham pointed to the conclusions of the later study and implied that they came from the earlier study."

Although Willingham denies that the CDC researcher, Dr. Verstraeten, was under pressure to alter the results of the earlier study, Dr. Hooker points out that Verstraeten's own email written at the time (an internal CDC document obtained through FOIA) reveals otherwise. Verstraeten's subject line, "It just won't go away," refers to his difficulty in making the statistical association between Thimerosal and autism disappear.

Making an example of how he says Dr. Verstraeten hid that association in his reanalysis of the data on 400,000 infants, Dr. Hooker says Verstraeten did not include clinics within HMOs where there was a strong correlation between Thimerosal exposure and autism incidence. According to Hooker, "Willingham brazenly disregarded Verstraeten's own chilling words: 'All the harm is done in the first month [of life]…' He wrote those words about the study I obtained."  The abstracts of Verstraeten's two studies and further comment on the controversy can be viewed here.

Dr. Hooker says Willingham misrepresented the congressional record when she selected quotes from a 2007 U.S. Senate report which falsely asserted that allegations of a cover-up are unsubstantiated. He considers the U.S. House of Representatives' 2003 report titled Mercury in Medicine (the result of a 3-year investigation) a "scathing, 80-page indictment of the CDC regarding the Thimerosal coverup."  The report concludes, "Our public health agencies' failure to act is indicative of institutional malfeasance for self-protection and misplaced protectionism of the pharmaceutical industry."

Willingham treated Verstraeten's final, watered-down results as solid epidemiological evidence, when, according to Hooker, the final version of the Verstraeten study is fraught with statistical flaws, primarily "overmatching." He provided an example:  the cases and controls received the same vaccination schedule and the same Thimerosal dosage; thus, no true comparison could be made.  Hooker says this invalidates all of the analyses (done separately for HMOs A, B and C).

Willingham quoted Verstraeten's  2004 letter in the journal Pediatrics regarding his later, diluted study, omitting the fact that the CDC has used the study to exonerate Thimerosal despite Verstraeten calling the study "neutral."  In addition, the 2004 Institute of Medicine (IOM) Immunization Safety Review (ISR) committee report used this as the only U.S. epidemiological study (among the 5 studies) as the basis to reject the Thimerosal-autism hypothesis, shutting the door on any further research. 

"In light of Ms. Willingham's enthusiastic defense of mercury in vaccines despite conclusive evidence of its harm to children, it is ironic that the tagline for her column is 'I write about the science they are selling you.'" remarked Dr. Hooker. Thimerosal is still administered to pregnant women and infants via the flu shot.

Brian Hooker, PhD, PE is an associate professor of biology at Simpson University. His over 50 science and engineering papers have been published in internationally recognized, peer-reviewed journals. He has a son, aged 16, who developed normally but then regressed into autism after receiving Thimerosal-containing vaccines. Dr. Brian Hooker's investigative research is sponsored by the Focus Autism Foundation, which is dedicated to informing the public about the cause(s) of the autism epidemic and the rise of chronic illnesses. To learn more, visit focusautisminc.org and ashotoftruth.org,  an educational website sponsored by Focus Autism. 

AutismOne is co-sponsoring this message and is a non-profit 501(c)(3) organization that provides education and supports advocacy efforts for children and families touched by an autism diagnosis. To learn more, visit autismone.org.

Media Contact: Angela Medlin, A Shot of Truth, 1 866-498-2768, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Brian Hooker, PhD, PE

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Splunk basically takes machine data and we make it usable, valuable and accessible for everyone. The way that plays in DevOps is - we need to make data-driven decisions to delivering applications," explained Andi Mann, Chief Technology Advocate at Splunk and @DevOpsSummit Conference Chair, in this SYS-CON.tv interview at @DevOpsSummit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
"Logz.io is a log analytics platform. We offer the ELK stack, which is the most common log analytics platform in the world. We offer it as a cloud service," explained Tomer Levy, co-founder and CEO of Logz.io, in this SYS-CON.tv interview at DevOps Summit, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captur...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal ...
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software securi...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
"There is a huge interest in Kubernetes. People are now starting to use Kubernetes and implement it," stated Sebastian Scheele, co-founder of Loodse, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.